Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of Nipocalimab vs Efgartigimod in a Randomized, Open-label, Phase 3b, Interventional Trial Including Within Class Switching From Efgartigimod to Nipocalimab

Next Previous
Trial Profile

Efficacy and Safety of Nipocalimab vs Efgartigimod in a Randomized, Open-label, Phase 3b, Interventional Trial Including Within Class Switching From Efgartigimod to Nipocalimab

Status: Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nipocalimab (Primary) ; Efgartigimod alfa; Efgartigimod alfa
  • Indications Myasthenia gravis
  • Focus Pharmacodynamics; Registrational
  • Acronyms EPIC
  • Sponsors Janssen Research & Development

Most Recent Events

  • 29 Oct 2025 According to the Johnson and Johnson Media Release, study design will present at the 2025 Myasthenia Gravis Foundation of America (MGFA) Scientific Session and the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting.
  • 29 Oct 2025 According to the Johnson and Johnson Media Release, company plans to initiate this trial.
  • 21 Oct 2025 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top